Volume 12 Issue 5, November 2018

Biotech company Actinogen Medical is developing Xanamem, a drug designed to inhibit the increased production of cortisol in the brain, which has been linked to cognitive decline and Alzheimer’s disease.

Taking a patient-centered approach, Indivior is developing innovative treatments for addiction to opioids, alcohol, and stimulants, as well as accompanying illnesses such as schizophrenia.

A novel, disease-modifying Alzheimer’s disease therapeutic, designed by KalGene Pharmaceuticals, could be the breakthrough sought by both patients and clinicians.

With multiple products in advanced clinical stages, including oral calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors, Biohaven is advancing collaborations on these programs and broadening its pipeline.

The Cuban Center for Neurosciences (CNEURO), a core institute of the Cuban organization of Biotechnology and Pharmaceutical Industries, BioCubaFarma, has developed a portfolio of technologies and services to diagnose and treat brain disorders and promote mental health from infancy to old age.

Fortuna Fix develops ethical, directly reprogrammed neural cell therapeutics manufactured on proprietary platform robotics allowing end-to-end manufacturing at high precision and scale.

Unlike standard analgesics, the company’s lead compound ricolinostat is a disease-modifying therapy that reverses nerve damage and reduces pain, numbness, and muscle weakness resulting from diabetes, chemotherapy, and Charcot–Marie–Tooth disease.

M3 Biotechnology is advancing a novel, potentially transformative approach for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Unlike other products approved and in development, M3’s drug candidates hold the potential to reverse or halt the degenerative process.

Continuing our dealmaking series, we explore one of the initial stages—finding a suitable partner—and provide advice on attracting and selecting the right match for your company and products.

Cryoport’s experience in cold chain logistics is now facing its biggest challenge yet—keeping patients’ therapies safe from damage in the revolutionary new field of cell therapy.

Based on its unique Enable enFuse technology, Enable Injections is developing body-worn small devices that enable patients to self-administer high-viscosity drugs conveniently throughout the day upon activation.

Providing a vast range of custom biologic services, including plasmid DNA production, mRNA production and antibody development, Aldevron is helping companies worldwide lay the foundations for groundbreaking science and discoveries.

The precision genetics medicine company Mediphage has developed an innovative DNA ministrings platform for safe, effective, and accessible ex vivo (cell) and in vivo (gene) therapies, including chimeric antigen receptor T-cells (CAR-Ts), CRISPR/Cas, and pluripotent stem-cell therapeutic applications.

TAGCyx Biotechnologies uses its proprietary Xenoligo technology platform to generate novel DNA aptamers containing an artificial nucleotide that have high affinity and selectivity for target proteins. TAGCyx is building a pipeline of Xenoligo aptamers and aptamer–drug conjugates, and is looking for global pharmaceutical partners.

In 2017 Grünenthal generated global revenues of €1.3 billion and signed around 50 partnering deals, positioning it as one of the leading companies to partner with for the development of pain therapeutics.

With extensive industry expertise, Dark Horse Consulting provides strategic and technical services to help clients realize their goals of bringing therapies to patients and commercialization.

Inmunotek has brought a range of skills and scientific specialties together to create a vaccinebased approach for the treatment of allergies and other immune-based diseases.

ImmunoPrecise offers a comprehensive suite of solutions to rapidly deliver high-performing therapeutic antibodies. The company works on royalty-free contract research agreements and partnership models.